Analysts Offer Insights on Healthcare Companies: ProKidney (PROK), Molecular Partners (MOLN) and Bristol-Myers Squibb (BMY)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ProKidney (PROK), Molecular Partners (MOLN) and Bristol-Myers Squibb (BMY).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ProKidney (PROK)
In a report released today, Dina Ramadane from Bank of America Securities maintained a Sell rating on ProKidney. The company’s shares closed last Wednesday at $2.08.
According to TipRanks.com, Ramadane is a 2-star analyst with an average return of
ProKidney has an analyst consensus of Hold, with a price target consensus of $7.33, a 245.8% upside from current levels. In a report released today, TipRanks – PerPlexity also reiterated a Sell rating on the stock with a $2.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Molecular Partners (MOLN)
In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Molecular Partners, with a price target of $12.00. The company’s shares closed last Wednesday at $4.55, close to its 52-week low of $3.32.
According to TipRanks.com, Zhu is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Molecular Partners with a $11.00 average price target, implying a 137.6% upside from current levels. In a report issued on March 13, Clear Street also maintained a Buy rating on the stock with a $8.00 price target.
Bristol-Myers Squibb (BMY)
Goldman Sachs analyst Asad Haider maintained a Hold rating on Bristol-Myers Squibb on March 17 and set a price target of $61.00. The company’s shares closed last Wednesday at $59.37, close to its 52-week high of $63.33.
According to TipRanks.com, Haider is a 4-star analyst with an average return of
Currently, the analyst consensus on Bristol-Myers Squibb is a Moderate Buy with an average price target of $62.67, representing a 5.6% upside. In a report issued on March 6, Citi also maintained a Hold rating on the stock with a $64.00 price target.
Read More on PROK:
Disclaimer & DisclosureReport an Issue
- ProKidney: Extended Development Timeline and Deferred Catalysts Support Balanced Hold Rating
- ProKidney reports Q4 EPS (52c), consensus (15c)
- Optimized PROACT 1 Design, Preserved Statistical Power, and Clear Regulatory Path Support Buy Rating on ProKidney
- ProKidney: Preserved Long-Term Opportunity but Heightened Timeline Risk Supports Continued Hold Rating
- ProKidney Expands Phase 3 REGEN-006 Trial Enrollment Plans
